New Insight with Dr. Veeral Sheth

Diabetes Dialogue

Don’t Miss a Beat

Crisis Point

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

A radiomics model was able to distinguish patients with and without gout flares 

in a new analysis and may have potential in facilitating the clinical decision-making process for treating gout.

“Radiomics, an innovative data analysis technique that quantifies characteristics via the high-throughput extraction of quantitative features from medical images, can fully exploit in-depth information on a wide range of diseases. Studies on knee osteoarthritis have shown that radiomics can successfully predict disease onset and deterioration, as well as progressive pain and structural changes, by extracting features from scanning images. However, there are currently no published data on the potential link between gout flares and Dual-energy computed tomography (DECT) radiomic features,” lead investigator Yabin Hu, Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, China, and colleagues wrote.

Hu and colleagues included 200 patients in their analysis (99% male), 150 of whom had experienced at least 1 confirmed gout flare in the past 12 months and 50 of whom did not. They extracted and analyzed the radiomic features of the tophi at the bilateral first metatarsophalangeal joints, selecting optimal radiomic features using the least absolute shrinkage and selection operator method. They used logistic regression analysis to screen clinical characteristics and establish a clinical model. The clinical model was then combined with the optimal radiomic to develop a comprehensive model. The radiomic, clinical, and comprehensive models were evaluated for performance using receiver operating characteristic curve analysis, calibration curves, and decision curve analysis.

The investigators found that there were 4 radiomic features that distinguished patients with at least 1 flare from those without flares; these were used to establish the radiomic model. Disease duration and hypertension were also found to be independent factors that differentiated flare occurrences, and these characteristics informed the clinical model. 

The radiomic, clinical, and comprehensive models showed favorable flarediscrimination, with the radiomic model having an area under the receiver operating characteristic curve (AUC) of 0.76 (95% CI, 0.69-0.83), the clinical model having an AUC of 0.72(95% CI, 0.63-0.80), and the comprehensive model having an AUC of 0.79 (95% CI, 0.73-0.86). The differentiated values of the comprehensive model agreed well with the actual values as seen on calibration curves (

 >.05). Overall, the comprehensive model achieved higher net clinical benefits than the use of either the radiomic or clinical model alone according to decision curve analysis.

“This is the first study to use radiomic features extracted from DECT to distinguish the occurrence of gout flares. We constructed and validated a comprehensive model, which comprised both radiomic features and clinical characteristics, that exhibited a favorable discrimination capability between flares and non-flares,” Hu and colleagues wrote.

 “Enhancing multi-machine and multicenter reproducibility, multi-reader reproducibility, and imaging reconstruction and processing methods should be addressed by future work.”

Other recent research examining clinical decision making in people with gout found that a 

 was a feasible and valid option when compared with the 2016 preliminary gout remission definition when compared in a study of nurse-led and usual (general practitioner) care.

Overall, 9.9% of participants achieved remission defined by the 2016 preliminary definition at Year 1 and 28.4% achieved it at Year 2 (

 <.001). More participants achieved remission according to the simplified definition (17.6% at Year 1 and 42.7% at Year 2; 

 <.001). Participants that achieved remission according to either definition had better gout outcomes via the GIS, including greater control over their gout, worry about future gout attacks, gout disease progression and its interference in future activities, and efficacy of gout medication, than those who did not.

Hu Y, Liu S, Ren W, et al. Dual-energy computed tomography-based radiomics for differentiating patients with and without gout flares. 

. Published online October 5, 2024. doi:10.1007/s10067-024-07166-1

Tabi-Amponsah AD, Doherty M, Sarmanova A, et al. Post-hoc analysis of two gout remission definitions in a two-year randomized controlled trial of nurse-led versus usual gout care. 

2024(16):152555. doi: 10.1016/j.semarthrit.2024.152555

Articles

A radiomics model utilizing DECT was developed to differentiate patients with and without gout flares, showing potential in clinical decision-making. The study involved 200 patients, analyzing radiomic features of tophi and clinical characteristics like disease duration and hypertension. The comprehensive model, combining radiomic and clinical data, demonstrated superior flare discrimination with an AUC of 0.79. This model outperformed individual models in net clinical benefits. Future research should focus on enhancing reproducibility and imaging methods. Additionally, a simplified gout remission definition showed feasibility and validity in clinical decision-making.

A comprehensive model of clinical and radiomic features was more accurate in distinguishing flares than either model alone.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Gout

On the HCPLive gout page, resources on the topics of medical news and expert insight into gouty arthritis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on gout, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Radiomics Model Distinguishes Gout Flares, May Improve Clinical Decision Making

 and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at 

Optimal utilization of guideline-directed medical therapy (GDMT) in 

 could significantly benefit global mortality rates, according to a new report published in 

This report showed an improved implementation of GDMT could prevent an estimated 1.19 million deaths per year on a global scale, with more than 1 million deaths prevented in regions including the Eastern Mediterranean and Africa, Southeast Asia, and the Western Pacific.

“This study highlights significant population-level mortality benefits with optimization of GDMT quadruple therapy on a global level and provides insights on regional differences that may better inform worldwide efforts for heart failure management,” wrote the investigative team, led by Gregg C. Fonarow, MD, division of cardiology, UCLA.

Global underutilization of GDMT has been reported, despite its strong benefits for efficacy and mortality rates.

 Previous investigations into the mortality benefits of the individual components of GDMT have mainly focused on the US, making the projected benefits of global GDMT optimation for heart failure with reduced ejection fraction (HFrEF) unknown.

For this analysis, Fonarow and colleagues sought to evaluate the projected benefit of optimal GDMT use in a worldwide population with HFrEF.

 The number of patients eligible for GDMT was determined based on estimates of heart failure prevalence from the Global Burden of Disease study. Those with contraindications to GDMT were estimated from US registries and applied globally.

Treatment rates and the number needed to treat for all-cause mortality at 12 months were calculated from previously published methods. Approximately 29 million people are estimated to have HFrEF worldwide, of which 8,235,063 and 12,223,700 were potentially eligible for, but not receiving β-blockers or angiotensin receptor–neprilysin inhibitors (ACEI/ARB), respectively.

Further estimates showed 12,223,700 and 21,229,170 individuals were eligible for, but not receiving mineralocorticoid receptor antagonists (MRA) or sodium-glucose cotransporter-2 (SGLT2) inhibitors.

Upon analysis, the optimal implementation of quadruple GDMT therapy on a global scale could save an estimated 1,188,277 lives over 12 months, particularly in the prevention of cardiovascular mortality. Benefits were most apparent in Southeast Asia and the Western Pacific, for a combined 720,054 averted deaths.

Fonarow and colleagues found angiotensin receptor-neprilysin inhibitors (ARNIs) and SGLT2 inhibitors comprised the largest proportion of averted deaths, at 29.5% and 28.4%, respectively. On the other hand, the optimal use of β-blockers saved approximately 24.8% of lives, while MRAs led to 17.4% of total lives saved globally.

The investigative team noted the rates of lives saved with optimal GDMT utilization were partially driven by the fact that a notable proportion of the global HFrEF population live in these regions, but experience low current treatment rates. These data suggest the heterogeneity of GDMT use globally and the potential magnitude of improvement with better GDMT utilization.

“Although future studies are needed to better understand the heterogeneity that exists within each region and potential interventions targeted to different settings, these findings demonstrate the urgent need for improved implementation of GDMT therapies worldwide,” they wrote.

Tang AB, Ziaeian B, Butler J, Yancy CW, Fonarow GC. Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure. JAMA Cardiol. Published online October 02, 2024. doi:10.1001/jamacardio.2024.3023

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in J Am Coll Cardiol. 2023 Apr 18;81(15):1551. doi: 10.1016/j.jacc.2023.03.002]. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012

Fonarow GC, Yancy CW, Hernandez AF, Peterson ED, Spertus JA, Heidenreich PA. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J. 2011;161(6):1024-30.e3. doi:10.1016/j.ahj.2011.01.027

Optimal implementation of guideline-directed medical therapy (GDMT) in heart failure could prevent approximately 1.19 million deaths annually worldwide, with significant benefits in regions like Southeast Asia and the Western Pacific. Despite its efficacy, GDMT is underutilized globally, particularly in heart failure with reduced ejection fraction (HFrEF). The study highlights the potential mortality reduction with optimal GDMT use, emphasizing the need for improved implementation. Angiotensin receptor-neprilysin inhibitors and SGLT2 inhibitors contribute most to mortality reduction, underscoring regional disparities in GDMT application and the urgent need for global optimization.

Optimal use of GDMT therapy in heart failure could save an estimated 1.19 million lives globally over the course of 1 year.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Optimizing GDMT in Heart Failure Could Slash Global Mortality Rates

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

Adrenaline auto-injectors have little effect on fatal 

 rates, according to new findings, and the injectors’ lack of a sustained plasma adrenaline concentration suggests a need for alternatives for adrenaline infusion.

These findings represented the conclusion of new research published in Clinical & Experimental Allergy evaluating self-administered auto-injectors and their implementation among individuals with 

 resulting in anaphylaxis. The study was led by Marcus Sim, MD, from the National Heart and Lung Institute at Imperial College London.

Sim and colleagues noted that anaphylaxis, an acute systemic hypersensitivity reaction to various allergens, is typically associated with such conditions as nausea, breathing issues, and shock. They added that those who suffer from this condition are often prescribed adrenaline (epinephrine) autoinjectors like EpiPens.

“The experience of anaphylaxis, and ongoing risk of further episodes can have a significant impact on mental health and quality of life,” Sim et al. wrote. “In this article, we review the role of adrenaline in anaphylaxis management, and explore the effectiveness of (adrenaline auto-injectors) for preventing fatal outcome.”

Autoinjectors were described by the investigators as having originally been developed in the 1960s for the American military, with rapid administration of intramuscular (IM) atropine being provided to individuals to counteract the impact of nerve agents. The EpiPen in the present day dominated the adrenaline auto-injector market up until US Food and Drug Administration (FDA) approvals led to the Adrenaclick and Auvi-Q also being widely marketed.

The research team pointed to parallels between the lack of randomized controlled trial evidence for the mortality reductions of auto-injectors and of parachutes, though they wrote that these situations differ. The team highlighted survival without a parachute is nearly impossible, yet anaphylaxis often resolves on its own without intervention.

Additionally, the investigators point to the general rarity of severe outcomes such as mortality or long-term neurodisability in anaphylaxis, adding that the mechanisms behind fatal situations are not well understood. The team highlighted that this causes difficulties in the establishment of surrogate markers for potentially deadly cases of anaphylaxis.

The evidence in support of adrenaline auto-injectors’ prevention of fatal anaphylaxis mainly comes from animal research, epidemiological data, and smaller human observational studies. Data was highlighted by the investigators suggesting that intravenous adrenaline infusions, commonly provided for patients at doses ranging from 0.05 - 0.5 μg/kg/min for 1–2 hours (or approximately 10 μg/kg total), are effective in physiological effect reversal in cases of anaphylaxis.

The research team also found that similar adrenaline levels, with a range between 100 - 500 pg/mL, can be successfully achieved through the use of intramuscular injection. However, the team noted that such levels are typically shown to be short-lived, adding that there is a general unpredictability of the pharmacokinetics and pharmacodynamics.

Epidemiological data highlighted by the investigators indicated that the incidence of visits to emergency departments, anaphylaxis, and hospitalizations resulting from instances of anaphylaxis have risen during recent decades. This has been particularly true in cases of childhood food anaphylaxis.

Nevertheless, a notable finding reported by the research team is that the overall rate of fatal anaphylaxis has continued to be relatively stable. The team added that there is no clear evidence suggesting an association between the rise in prescriptions for auto-injectors and a reduction in fatal anaphylaxis.

The investigators added that the rates at which individuals carry and implement auto-injector devices remains low. All of these findings indicate that current adrenaline auto-injectors may have limited influence on cases of fatal anaphylaxis, and the team noted that this may be due to their inability to maintain adequate plasma adrenaline concentrations.

Lastly, the research team highlighted the fact that the effect of device prescriptions on quality of life appears to vary.

“Consistent with the findings from in vivo studies in humans, dogs and rats, the steady increase in (adrenaline auto-injectors) availability over the past 35 years has not been accompanied by an equivalent reduction in population rates of fatal anaphylaxis,” they wrote. “Thus, (adrenaline auto-injectors) may not be reliably effective for preventing fatal anaphylaxis.”

Sim M, Sharma V, Boyle R, et al (2024). Adrenaline Auto-Injectors for Preventing Fatal Anaphylaxis. Clin Exp Allergy. https://doi.org/10.1111/cea.14565.

Can adrenaline auto-injectors prevent fatal anaphylaxis? EurekAlert! October 9, 2024. https://www.eurekalert.org/news-releases/1060201. Date accessed: October 9, 2024.

Adrenaline auto-injectors, such as EpiPens, have shown limited impact on reducing fatal anaphylaxis rates, as they fail to maintain sustained plasma adrenaline levels. Despite increased prescriptions and availability, the incidence of fatal anaphylaxis remains stable, with no clear evidence linking auto-injector use to reduced mortality. The unpredictability of pharmacokinetics and pharmacodynamics, along with low usage rates, may contribute to their limited effectiveness. Alternatives, such as intravenous adrenaline infusions, demonstrate more reliable physiological effects, suggesting a need for reevaluation of current anaphylaxis management strategies.

During situations in which those with severe allergies suffer from fatal anaphylaxis, adrenaline autoinjectors were shown in this study to have little effect on such reactions.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Study Finds Adrenaline Auto-Injectors Mostly Ineffective Against Fatal Anaphylaxis

Chelsie Derman is an assistant editor for 

who covers psychiatry, sleep medicine, and geriatrics. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A recent study found aberrant locus coeruleus functional connectivity (LC-FC) networks in patients with comorbid 

“These findings offer novel perspectives on the neuroimaging mechanisms underlying [comorbid migraine and insomnia],” wrote investigators, led by Changlin Wang, from the department of neurology at The First Affiliated Hospital of Anhui Medical University in China.

 The locus coeruleus is a brainstem region responsible for norepinephrine synthesis and modulates pain, sleep/wake cycles, and emotional regulation.

 It is believed this region is a possible nexus in the comorbidity of migraine and insomnia; people have hypothesized that disruptions in the locus coeruleus- noradrenergic system contribute to the comorbidities of migraine and insomnia.

However, there is limited neuroimaging evidence on this connection in humans. Investigators sought to investigate the intrinsic functional connectivity network of the locus coeruleus in patients with comorbid migraine and insomnia, as well as in patients with migraine and no insomnia. The team evaluated the functional connectivity through resting-state functional magnetic resonance imaging and seed-based analyses.

The cross-sectional study included 30 patients with comorbid migraine and chronic insomnia, 30 patients with migraine and no insomnia, and 30 healthy controls. Participants with migraine had no significant difference in behavioral performance and demographic characteristics, including age, sex, or education levels, between those with and without insomnia (P > .05). They also did not have significant differences in headache-related features, such as duration, frequency, attack duration, VAS, HIT score, and depression.

Compared with healthy controls, participants with migraines had greater SAS and SDS scores (P < .001). The scores were not significantly different between participants with and without insomnia (P > .05).

Investigators found patients with comorbid migraine and insomnia demonstrated altered LC-FC in several brain regions, including the dorsomedial prefrontal cortex, anterior cerebellum, dorsolateral prefrontal cortex, thalamus, and parahippocampal gyrus.

The team found a Pittsburgh Sleep Quality Index (PSQI) score is negatively correlated with the left LC-FC in the right parahippocampal gyrus (P = .0006). This indicates a lower functional connectivity between the locus coeruleus and the dorsolateral prefrontal cortex is linked to a greater insomnia severity.

“This finding suggests that LC-DLPFC connectivity may be a potential biomarker of sleep disturbance in patients with [comorbid migraine and insomnia],” investigators wrote.

The team also noted a positive correlation between PSQI and the right LC-FC in the caudate (P = .03), which demonstrates worse sleep quality is linked to greater connectivity in the caudate.

Additionally, greater functional connectivity between the locus coeruleus and the dorsomedial prefrontal cortex was associated with a longer migraine attack among participants with comorbid migraine and insomnia (P = .036).

“The observed enhanced functional connectivity between the LC and cerebellum may suggest alterations in trigeminal nociceptive processing and pain modulation within the LC in patients with MI,” investigators wrote. “However, further research is needed to confirm these potential mechanisms.”

Investigators wrote the study was limited by its cross-sectional design and the small sample size. They also added the study was limited by only conducting the MRIs from 4 pm to 10 pm as individuals with insomnia may have increased hyperarousal and anxiety closer to their typical sleep time. Completing the MRIs later in the day may have impacted the functional data.

Other key limitations included using subjective insomnia measures rather than objective measures such as polysomnography and using 3T fMRI which lacks the resolution for small subcortical structures, are key limitations.

“The identified LC-FC alterations may serve as potential targets for therapeutic interventions and highlight the importance of considering the LC-noradrenergic system in the management of [comorbid migraine and insomnia],” investigators concluded.

Wang C, Chen S, Cheng Z, et al. Characteristics of locus coeruleus functional connectivity network in patients with comorbid migraine and insomnia. 

. 2024;25(1):159. Published 2024 Sep 27. doi:10.1186/s10194-024-01877-1

Grossi, G. Chronic Migraine and Insomnia Have a Strong Bidirectional Relationship. 

https://www.hcplive.com/view/chronic-migraine-insomnia-strong-bidirectional-relationship

The study explored aberrant locus coeruleus functional connectivity (LC-FC) networks in patients with comorbid migraine and insomnia, revealing altered connectivity in several brain regions. The locus coeruleus, a brainstem region involved in norepinephrine synthesis, is implicated in pain, sleep/wake cycles, and emotional regulation. Findings suggest LC-FC alterations may serve as potential biomarkers and therapeutic targets for managing comorbid migraine and insomnia. However, the study's cross-sectional design, small sample size, and reliance on subjective insomnia measures limit its conclusions, necessitating further research.

Comorbid migraine and insomnia are linked to altered locus coeruleus connectivity, suggesting it is a biomarker for sleep disturbances and a potential therapeutic target.

Migraine

The HCPLive migraine page is a comprehensive resource for clinical news and insights on migraine headaches. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for migraines, and more.

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

Comorbid Migraine, Insomnia Linked to Aberrant Locus Coeruleus Functional Connectivity

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Updates in Primary Biliary Cholangitis Care

 treatment landscape has undergone significant developments in the past few months with the addition of a pair of newly FDA-approved peroxisome proliferator-activated receptor (PPAR) agonists, elafibranor (Iqirvo) and seladelpar (Livdelzi).

Although ursodeoxycholic acid (UDCA) has long served as the first-line treatment for patients with PBC and has demonstrated a notable impact on transplant-free survival as well as the development of fibrosis and esophageal varices, many patients do not have an adequate response to treatment or are unable to tolerate it, underscoring the need for second-line therapies.

Since it was first granted FDA accelerated approval in 2016, obeticholic acid (Ocaliva) has been the only second-line treatment option in PBC. However, following a negative opinion from a US Food and Drug Administration Gastrointestinal Drug Advisory Committee and with a quickly-approaching October 15, 2024, Prescription Drug User Fee Act (PDUFA) target action date looming around the corner, obeticholic acid’s future in PBC appears to be less than certain.

“It's very important to have second-line treatments available. If someone is unable to tolerate the first-line treatment, we want to be able to provide them with something,” Allysa Saggese, NP, a nurse practitioner in liver disease and transplantation at Weill Cornell Medicine, explained to 

. “The goal here is to normalize alkaline phosphatase. That's been a big discussion in the community, and we want to be able to provide some way to do that.”

Although she noted the impact of the approvals of elafibranor and seladelpar is still evolving, Saggese described these developments as “exciting,” citing the potential benefits of having more options to offer patients who may be intolerant to both ursodeoxycholic acid and obeticholic acid.

She went on to point out how treatment goals have shifted from alkaline phosphatase ≤1×upper limit of normal to alkaline phosphatase normalization, also describing accelerated treatment timelines because of how rapidly the newer second-line therapies have shown improvement in clinical trials as well as what conversations about treatment with patients look like with so many therapies now available to them.

“One thing that I keep learning through discussing all of the medications, treating my patients, and being a part of the trials is that we might need to be more conscious of how we are talking about PBC symptoms,” Saggese said, describing her own experiences inquiring about itch and the importance of making patients aware that it may be a symptom or side effect of PBC. “We need to make sure we're providing the most comprehensive kind of care for these patients.”

Brooks, A. FDA Grants Accelerated Approval to Elafibranor (Iqirvo) for PBC. 

. June 10, 2024. Accessed October 8, 2024. 

https://www.hcplive.com/view/fda-grants-accelerated-approval-to-elafibranor-iqirvo-for-pbc

Brooks, A. FDA Grants Accelerated Approval to Seladelpar (Livdelzi) for Primary Biliary Cholangitis. 

. August 14, 2024. Accessed October 8, 2024. 

https://www.hcplive.com/view/fda-grants-accelerated-approval-to-seladelpar-livdelzi-for-primary-biliary-cholangitis

Brooks, A. Nancy Reau, MD: Obeticholic Acid’s Future in PBC After FDA Advisory Committee Meeting. HCPLive. September 20, 2024. Accessed October 8, 2024. 

https://www.hcplive.com/view/nancy-reau-md-obeticholic-acid-future-pbc-fda-advisory-committee-meeting

Videos

Recent advancements in primary biliary cholangitis (PBC) treatment include the FDA approval of two new PPAR agonists, elafibranor and seladelpar. While ursodeoxycholic acid remains the first-line treatment, many patients require alternative therapies due to inadequate response or intolerance. Obeticholic acid, previously the sole second-line option, faces an uncertain future. The introduction of new therapies has shifted treatment goals towards alkaline phosphatase normalization. These developments highlight the importance of comprehensive patient care and awareness of PBC symptoms, such as itch, to optimize treatment outcomes.

Saggese explains the importance of second-line therapies in PBC, newly approved treatment options, and their impact on treatment goals and timelines.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Updates in Primary Biliary Cholangitis Care, with Allysa Saggese, NP

HCPLive spoke with Maguire about the benefits of acetylcholine and muscarinic receptors for the treatment of schizophrenia.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Gerald Maguire, MD: The Future of Acetylcholine and Muscarinic Receptors

This Month in Review article featured a variety of notable updates in the field of pulmonology covered in September 2024.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonology Month in Review: September 2024

Sam Clark, MD, PhD, is a former practicing psychiatrist and the founder of Terran Biosciences. 

In part 5 of 5, experts discuss ongoing unmet needs and future research priorities in schizophrenia management.

FDA News

Video Series

Unmet Needs, Future Research in Schizophrenia and Muscarinic Agonists

In part 4 of 5, experts discuss medication adherence to schizophrenia treatments, particularly of xanomeline and trospium choloride capsules for schizophrenia.

Balancing the Benefits and Risks of Xanomeline and Trospium Chloride Capsules

In part 3 of 5, experts discuss the pivotal trials evaulating xanomeline and trospium chloride capsules (Cobenfy) for schizophrenia.

Applying EMERGENT Trial Results to Real-World Clinical Practice for Schizophrenia

In part 2 of 5, experts discuss the unique mechanism of xanomeline and trospium choloride capsules for the treatment of schizozphrenia.

Mechanism of Action of Xanomeline and Trospium Chloride Capsules in Schizophrenia

In part 1 of 5, panel moderator gives an overview of the Special Report focusing on the approval of Xanomeline and tropism chloride capsules for schizophrenia.

Embracing New Therapies in Schizophrenia Management: Introductions

Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Dyslipidemia

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Time-Restricted Eating Shows Promise for Metabolic Syndrome in 3-Month Trial

Education and employment, social and emotional functioning, and healthcare access are notable factors influencing pain in sickle cell disease.

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Anemia

Hematology

Social Determinants of Health Shape Pain Outcomes in Sickle Cell Disease

In the allergy news space, this Month in Review highlights some of the most significant stories covered by the editorial team.

Latest News

Radiomics Model Distinguishes Gout Flares, May Improve Clinical Decision Making

Optimizing GDMT in Heart Failure Could Slash Global Mortality Rates

Study Finds Adrenaline Auto-Injectors Mostly Ineffective Against Fatal Anaphylaxis

Comorbid Migraine, Insomnia Linked to Aberrant Locus Coeruleus Functional Connectivity

Updates in Primary Biliary Cholangitis Care, with Allysa Saggese, NP